{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "9106259",
  "DateCompleted": {
    "Year": "1997",
    "Month": "07",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "08",
    "Day": "31"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0197-0186",
      "JournalIssue": {
        "Volume": "30",
        "Issue": "4-5",
        "PubDate": {
          "Year": "1997",
          "Season": "Apr-May"
        }
      },
      "Title": "Neurochemistry international",
      "ISOAbbreviation": "Neurochem Int"
    },
    "ArticleTitle": "Naloxone differentially alters fevers induced by cytokines.",
    "Pagination": {
      "StartPage": "441",
      "EndPage": "448",
      "MedlinePgn": "441-8"
    },
    "Abstract": {
      "AbstractText": [
        "Interferon-alpha (IFN-alpha), a cytokine acting as an endogenous pyrogen and a putative activator of the opioid system, binds to opiate receptors in vitro. The mu opioid receptor antagonist, naloxone hydrochloride (NLX), attenuates IFN-alpha-induced increases in the firing rate of cold-sensitive neurons within thermosensitive areas of the brain. The influence of NLX on fevers induced by central endogenous pyrogens was investigated in rats. Subcutaneous (SQ) injection of NLX (1 mg/kg) was made 30 min prior to intracerebroventricular (ICV) injection of IFN-alpha 2b (7900IU). Alternatively, NLX (10 or 80 micrograms) was microinjected ICV 30 min prior to administration of IFN-alpha 2b. Administered SQ, NLX attenuated the febrile response to IFN-alpha 2b. In contrast, central (ICV) NLX did not attenuate fevers induced by IFN-alpha 2b. Animals previously exposed to both IFN-alpha 2b and NLX (SQ or ICV) subsequently lost their sensitivity to this cytokine, and also showed diminished reactivity to human recombinant interleukin-1 beta (hrIL-1 beta; 10 ng) and prostaglandin E2 (PGE2; 250 ng). These results suggest that systemic and central elements of the opioid system may play differential roles in temperature regulation. Previous administration of NLX and IFN-alpha 2b may alter the sensitivity of the CNS to subsequent injections of different pyrogens."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, University of Colorado School of Medicine, Denver 80262, USA."
          }
        ],
        "LastName": "Zawada",
        "ForeName": "W M",
        "Initials": "WM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Clarke",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ruwe",
        "ForeName": "W D",
        "Initials": "WD"
      }
    ],
    "GrantList": [
      {
        "GrantID": "NS 26045",
        "Acronym": "NS",
        "Agency": "NINDS NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Research Support, U.S. Gov't, P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Neurochem Int",
    "NlmUniqueID": "8006959",
    "ISSNLinking": "0197-0186"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interferon-alpha"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interleukin-1"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Narcotic Antagonists"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Recombinant Proteins"
    },
    {
      "RegistryNumber": "36B82AMQ7N",
      "NameOfSubstance": "Naloxone"
    },
    {
      "RegistryNumber": "K7Q1JQR04M",
      "NameOfSubstance": "Dinoprostone"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "pharmacology"
      ],
      "DescriptorName": "Dinoprostone"
    },
    {
      "QualifierName": [
        "chemically induced",
        "metabolism"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Injections, Intraventricular"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "pharmacology"
      ],
      "DescriptorName": "Interferon-alpha"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "pharmacology"
      ],
      "DescriptorName": "Interleukin-1"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Naloxone"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Narcotic Antagonists"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats, Sprague-Dawley"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "pharmacology"
      ],
      "DescriptorName": "Recombinant Proteins"
    }
  ]
}